Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

DURHAM, N.C., Jan. 5, 2023 – Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 p.m. PT in San Francisco, CA.

Investors can access an audio webcast of this presentation on Chimerix's Investor Relations website, where it will be archived for about 90 days. Chimerix focuses on developing medicines that improve the lives of patients with severe diseases, with its leading program, ONC201, targeting H3 K27M-mutant glioma.

News Market Reaction – CMRX

-4.66%

-4.66% Session move

In the trading session that priced this news, CMRX declined 4.66%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41^st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:   

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Nick Lamplough / Dan Moore / Tanner Kaufman
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

FAQ

When will Chimerix present at the J.P. Morgan Healthcare Conference?

Chimerix will present at the J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 p.m. PT.

Where can I watch the Chimerix conference presentation?

The presentation can be accessed via an audio webcast on Chimerix's Investor Relations website.

What is Chimerix's main drug development focus?

Chimerix is primarily focused on developing ONC201 for H3 K27M-mutant glioma.

What is the stock symbol for Chimerix?

The stock symbol for Chimerix is CMRX.